Literature DB >> 28275494

Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus.

Nousheen Iqbal1, Muhammad Irfan1, Kauser Jabeen2, Murtaza Mohammed Kazmi1, Muhammad Usman Tariq3.   

Abstract

Mucormycosis commonly affects immunocompromised individuals with defects in neutrophil function or count. Diabetes mellitus is an important risk factor due to impair innate and acquired immunity for mucormycosis, with rhino-orbital-cerebral involvement as a common presentation. Pulmonary mucormycosis (PM) although a rare presentation in diabetic patients but is associated with high mortality and morbidity. An early diagnosis of PM is difficult, due to rarity of the disease and clinical and radiological features resembling tuberculosis (TB) which is common in Pakistan. Here we present three cases of chronic PM in patients with diabetes and with no other apparent risk factors.

Entities:  

Keywords:  Diabetes; immunocompromised; pulmonary mucormycosis (PM)

Year:  2017        PMID: 28275494      PMCID: PMC5334082          DOI: 10.21037/jtd.2017.02.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  17 in total

1.  Pulmonary mucormycosis: two of a kind.

Authors:  Ritesh Agarwal; Vijay Kumar; D Gupta
Journal:  Eur J Intern Med       Date:  2006-01       Impact factor: 4.487

2.  Pulmonary mucormycosis presenting as nonresolving pneumonia in a patient with diabetes mellitus.

Authors:  Manoj K Panigrahi; Rajaram Manju; Saka Vinod Kumar; Pampa C Toi
Journal:  Respir Care       Date:  2014-07-08       Impact factor: 2.258

3.  A prospective study of mucormycosis in north India: experience from a tertiary care hospital.

Authors:  Kiran Bala; Jagdish Chander; Uma Handa; Rajpal Singh Punia; Ashok Kumar Attri
Journal:  Med Mycol       Date:  2015-01-13       Impact factor: 4.076

Review 4.  Histopathologic diagnosis of fungal infections in the 21st century.

Authors:  Jeannette Guarner; Mary E Brandt
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 5.  Pulmonary mucormycosis: the last 30 years.

Authors:  F Y Lee; S B Mossad; K A Adal
Journal:  Arch Intern Med       Date:  1999-06-28

Review 6.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 7.  Pulmonary mucormycosis: results of medical and surgical therapy.

Authors:  M Tedder; J A Spratt; M P Anstadt; S S Hegde; S D Tedder; J E Lowe
Journal:  Ann Thorac Surg       Date:  1994-04       Impact factor: 4.330

8.  Surgery for localized pulmonary mycotic infections in patients with hematopoietic disorder.

Authors:  Youngkyu Moon; Jae Kil Park; Sook Whan Sung
Journal:  J Cardiothorac Surg       Date:  2015-06-30       Impact factor: 1.637

9.  Pulmonary tuberculosis and mucormycosis co-infection in a diabetic patient.

Authors:  Deepak Aggarwal; Jagdish Chander; Ashok K Janmeja; Rahul Katyal
Journal:  Lung India       Date:  2015 Jan-Feb

10.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

Authors:  O A Cornely; S Arikan-Akdagli; E Dannaoui; A H Groll; K Lagrou; A Chakrabarti; F Lanternier; L Pagano; A Skiada; M Akova; M C Arendrup; T Boekhout; A Chowdhary; M Cuenca-Estrella; T Freiberger; J Guinea; J Guarro; S de Hoog; W Hope; E Johnson; S Kathuria; M Lackner; C Lass-Flörl; O Lortholary; J F Meis; J Meletiadis; P Muñoz; M Richardson; E Roilides; A M Tortorano; A J Ullmann; A van Diepeningen; P Verweij; G Petrikkos
Journal:  Clin Microbiol Infect       Date:  2014-04       Impact factor: 8.067

View more
  5 in total

1.  Candida albicans CHK1 gene from two-component system is essential for its pathogenicity in oral candidiasis.

Authors:  Yujie Zhou; Lei Cheng; Binyou Liao; Yangyang Shi; Yulong Niu; Chengguang Zhu; Xingchen Ye; Xuedong Zhou; Biao Ren
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-26       Impact factor: 4.813

Review 2.  Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.

Authors:  Valliappan Muthu; Ritesh Agarwal; Atul Patel; Soundappan Kathirvel; Ooriapadickal Cherian Abraham; Ashutosh Nath Aggarwal; Amanjit Bal; Ashu Seith Bhalla; Prashant N Chhajed; Dhruva Chaudhry; Mandeep Garg; Randeep Guleria; Ram Gopal Krishnan; Arvind Kumar; Uma Maheshwari; Ravindra Mehta; Anant Mohan; Alok Nath; Dharmesh Patel; Shivaprakash Mandya Rudramurthy; Puneet Saxena; Nandini Sethuraman; Tanu Singhal; Rajeev Soman; Balamugesh Thangakunam; George M Varghese; Arunaloke Chakrabarti
Journal:  Lancet Infect Dis       Date:  2022-04-04       Impact factor: 71.421

Review 3.  Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.

Authors:  Asim Azhar; Wajihul Hasan Khan; Parvez Anwar Khan; Khaled Alhosaini; Mohammad Owais; Aijaz Ahmad
Journal:  J Infect Public Health       Date:  2022-02-18       Impact factor: 3.718

4.  Pulmonary Mucormycosis: A Case Report of a Rare Infection with Potential Diagnostic Problems.

Authors:  Salwa O Mekki; Amal A Hassan; Afnan Falemban; Nashwa Alkotani; Salem M Alsharif; Ahmed Haron; Basim Felemban; Mohammad S Iqbal; Aisha Tabassum
Journal:  Case Rep Pathol       Date:  2020-01-06

5.  Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study.

Authors:  Ngoc Thi Bich Nguyen; Huy Le Ngoc; Nhung Viet Nguyen; Luong Van Dinh; Hung Van Nguyen; Huyen Thi Nguyen; David W Denning
Journal:  J Fungi (Basel)       Date:  2021-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.